Fabiola De Marchi

Dr. Fabiola De Marchi

ALS Center & Department of Neurology, “Maggiore della Carità” Hospital, University of Piemonte Orientale (UPO), Via Solaroli 17 - Novara, Italy
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2022 in Drugs
Verified
Journal Article
Closed access
PDF file
SJStephen A. Johnson
Stephen A. Johnson
TFTon Fang
Ton Fang
FMFabiola De Marchi
Fabiola De Marchi
DNDylan Neel
Dylan Neel
DWDonatienne Mw. Van Weehaeghe
Donatienne Mw. Van Weehaeghe
SPSabrina Paganoni
Sabrina Paganoni

17 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JESSICA MANDRIOLIJESSICA MANDRIOLI
JESSICA MANDRIOLI
RDRoberto D’aMico
Roberto D’aMico
EZElisabetta Zucchi
Elisabetta Zucchi
SBSara De Biasi
Sara De Biasi
FBFederico Banchelli
Federico Banchelli
ACAndrea Cossarizza
Andrea Cossarizza
In preclinical studies rapamycin was found to target neuroinflammation, by expanding regulatory T cells, and affecting autophagy, two pillars of amyotrophic lateral sclerosis (ALS) pathogenesis. Herein we report a multicenter, randomized, double-blind trial, in 63 ALS patients who were randomly assigned in a 1:1:1 ratio to receive rapamycin 2 mg/m2/day,1 mg/m2/day or placebo (EUDRACT 2016-002399-28; NCT03359538). The primary outcome, the number of patients exhibiting an increase >30% in regulatory T cells from baseline to treatment end, was not attained. Secondary outcomes were changes from baseline of T, B, NK cell subpopulations, inflammasome mRNA expression and activation status, S6-ribosomal protein phosphorylation, neurofilaments; clinical outcome measures of disease progression; survival; safety and quality of life. Of the secondary outcomes, rapamycin decreased mRNA relative expression of the pro-inflammatory cytokine IL-18, reduced plasmatic IL-18 protein, and increased the percentage of classical monocytes and memory switched B cells, although no corrections were applied for multiple tests. In conclusion, we show that rapamycin treatment is well tolerated and provides reassuring safety findings in ALS patients, but further trials are necessary to understand the biological and clinical effects of this drug in ALS.

13 February 2021 in Brain Sciences
Verified
Journal Article
Open access
PDF file
FMFabiola De Marchi
Fabiola De Marchi
ECElena Contaldi
Elena Contaldi
LMLuca Magistrelli
Luca Magistrelli
RCRoberto Maria Cantello
Roberto Maria Cantello
Cristoforo ComiCristoforo Comi
Cristoforo Comi
LMLetizia Mazzini
Letizia Mazzini
Telehealth, by definition, is distributing health-related services while using electronic technologies. This narrative Review describes the technological health services (telemedicine and telemonitoring) for delivering care in neurodegenerative diseases, Alzheimer’s disease, Parkinson’s Disease, and amyotrophic lateral Sclerosis, among others. This paper aims to illustrate this approach’s primary experience and application, highlighting the strengths and weaknesses, with the goal of understanding which could be the most useful application for each one, in order to facilitate telehealth improvement and use in standard clinical practice. We also described the potential role of the COVID-19 pandemic to speed up this service’s use, avoiding a sudden interruption of medical care.

14 October 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
FMFabiola De Marchi
Fabiola De Marchi
Ivana MuniticIvana Munitic
Ivana Munitic
LVLea Vidatic
Lea Vidatic
EPEliša Papić
Eliša Papić
VRValentino Rački
Valentino Rački
SHSilva Hecimovic
Silva Hecimovic
Many potential immune therapeutic targets are similarly affected in adult-onset neurodegenerative diseases, such as Alzheimer’s (AD) disease, Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD), as well as in a seemingly distinct Niemann–Pick type C disease with primarily juvenile onset. This strongly argues for an overlap in pathogenic mechanisms. The commonly researched immune targets include various immune cell subsets, such as microglia, peripheral macrophages, and regulatory T cells (Tregs); the complement system; and other soluble factors. In this review, we compare these neurodegenerative diseases from a clinical point of view and highlight common pathways and mechanisms of protein aggregation, neurodegeneration, and/or neuroinflammation that could potentially lead to shared treatment strategies for overlapping immune dysfunctions in these diseases. These approaches include but are not limited to immunisation, complement cascade blockade, microbiome regulation, inhibition of signal transduction, Treg boosting, and stem cell transplantation.

7 October 2022 in European Journal of Neurology
Verified
Journal Article
Open access
EBEttore Beghi
Ettore Beghi
EPElisabetta Pupillo
Elisabetta Pupillo
EBElisa Bianchi
Elisa Bianchi
VBValentina Bonetto
Valentina Bonetto
SLSilvia Luotti
Silvia Luotti
TGthe RNS60‐ALS Study Group
the RNS60‐ALS Study Group
Background and purpose: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options. RNS60 is an immunomodulatory and neuroprotective investigational product that has shown efficacy in animal models of ALS and other neurodegenerative diseases. Its administration has been safe and well tolerated in ALS subjects in previous early phase trials.Methods: This was a phase II, multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Participants diagnosed with definite, probable or probable laboratory‐supported ALS were assigned to receive RNS60 or placebo administered for 24 weeks intravenously (375 ml) once a week and via nebulization (4 ml/day) on non‐infusion days, followed by an additional 24 weeks off‐treatment. The primary objective was to measure the effects of RNS60 treatment on selected biomarkers of inflammation and neurodegeneration in peripheral blood. Secondary objectives were to measure the effect of RNS60 on functional impairment (ALS Functional Rating Scale—Revised), a measure of self‐sufficiency, respiratory function (forced vital capacity, FVC), quality of life (ALS Assessment Questionnaire‐40, ALSAQ‐40) and survival. Tolerability and safety were assessed.Results: Seventy‐four participants were assigned to RNS60 and 73 to placebo. Assessed biomarkers did not differ between arms. The mean rate of decline in FVC and the eating and drinking domain of ALSAQ‐40 was slower in the RNS60 arm (FVC, difference 0.41 per week, standard error 0.16, p = 0.0101; ALSAQ‐40, difference –0.19 per week, standard error 0.10, p = 0.0319). Adverse events were similar in the two arms. In a post hoc analysis, neurofilament light chain increased over time in bulbar onset placebo participants whilst remaining stable in those treated with RNS60.Conclusions: The positive effects of RNS60 on selected measures of respiratory and bulbar function warrant further investigation.

Verified
Journal Article
Open access
PDF file
GTGiacomo Tondo
Giacomo Tondo
FMFabiola De Marchi
Fabiola De Marchi
FBFrancesca Bonardi
Francesca Bonardi
FMFederico Menegon
Federico Menegon
GVGaia Verrini
Gaia Verrini
Cristoforo ComiCristoforo Comi
Cristoforo Comi
Alzheimer’s disease (AD) causes a significant challenge to global healthcare systems, with limited effective treatments available. This review examines the landscape of novel therapeutic strategies for AD, focusing on the shortcomings of traditional therapies against amyloid-beta (Aβ) and exploring emerging alternatives. Despite decades of research emphasizing the role of Aβ accumulation in AD pathogenesis, clinical trials targeting Aβ have obtained disappointing results, highlighting the complexity of AD pathophysiology and the need for investigating other therapeutic approaches. In this manuscript, we first discuss the challenges associated with anti-Aβ therapies, including limited efficacy and potential adverse effects, underscoring the necessity of exploring alternative mechanisms and targets. Thereafter, we review promising non-Aβ-based strategies, such as tau-targeted therapies, neuroinflammation modulation, and gene and stem cell therapy. These approaches offer new avenues for AD treatment by addressing additional pathological hallmarks and downstream effects beyond Aβ deposition.